| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Gallium hematoporphyrin (GaHP) (0.5–1 μg/mL) inhibited the growth of clinically isolated Mycobacterium abscessus (both smooth and rough types) in iron-deficient 7H9 medium, with minimum inhibitory concentrations (MICs) of 0.5 and 1 μg/mL [1]. Gallium hematoporphyrin (0.0625 μg/mL; in combination with clarithromycin) showed synergistic effects against Mycobacterium abscessus, with an FIC of 0.31 for GaHP and 0.0625 μg/mL [1]. Gallium hematoporphyrin (at concentrations up to 32 μg/mL) was nontoxic to Vero E6 cells [1]. Gallium hematoporphyrin (1 μg/mL (1.5 μM); 65 h) inhibits the growth of Mycobacterium abscessus by targeting the heme utilization pathway, which has been confirmed by the recovery of growth after treatment with heme rather than fatty acid methyl ester (FAC) at a concentration of 1 μg/mL (1.5 μM) GaHP for 65 hours [1]. Gallium hematoporphyrin (0.03–16 μg/mL; 3 h) induces concentration-dependent reactive oxygen species (ROS) production in Mycobacterium abscessus after incubation at concentrations of 0.03–8 μg/mL for 3 hours, while ROS levels decrease due to cell death at 16 μg/mL [1]. Gallium hematoporphyrin (8 μg/mL) inhibits biofilm formation in iron-rich medium for both smooth and rough types of Mycobacterium abscessus, with an inhibition rate of approximately 60% for smooth strains and approximately 30% for rough strains [1]. Gallium hematoporphyrin (16 μg/mL) can disrupt the pre-formed biofilms of smooth and rough abscess mycobacteria morphologies, with a disruption rate of about 50% for smooth variant biofilms and about 40% for rough variant biofilms [1].
|
|---|---|
| References |
| Molecular Formula |
C34H38CLGAN4O6
|
|---|---|
| Molecular Weight |
703.86
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
CC1=C(C2=CC3=N4C(C(C)=C3CCC(O)=O)=CC5=C(C(C(O)C)=C6C=C7C(C)=C(C8=N7[Ga]4(N2C1=C8)(N56)Cl)C(O)C)C)CCC(O)=O
|
| Synonyms |
GaHP
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4207 mL | 7.1037 mL | 14.2074 mL | |
| 5 mM | 0.2841 mL | 1.4207 mL | 2.8415 mL | |
| 10 mM | 0.1421 mL | 0.7104 mL | 1.4207 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
